FindTrial
Sign In

Tesevatinib

DRUG7 trials

Sponsors

Kadmon, a Sanofi Company, Kadmon Corporation, LLC

Conditions

ADPKDAutosomal Dominant Polycystic KidneyAutosomal Dominant Polycystic Kidney Disease (ADPKD)Brain MetastasesBrain TumorGlioblastomaHER-2 Positive Breast CancerLeptomeningeal Metastases

Phase 1

A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease
CompletedNCT01559363
Kadmon, a Sanofi CompanyPolycystic Kidney, Autosomal Dominant
Start: 2012-10-11End: 2019-02-08Updated: 2022-11-08
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
TerminatedNCT02154529
Kadmon Corporation, LLCHER-2 Positive Breast Cancer, Metastatic Malignant Neoplasm to Brain
Start: 2014-05-31End: 2015-09-13Updated: 2022-04-27
A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
CompletedNCT03096080
Kadmon Corporation, LLCPolycystic Kidney, Autosomal Recessive
Start: 2017-08-24End: 2019-09-30Updated: 2022-05-11

Phase 2

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
TerminatedNCT02616055
Kadmon Corporation, LLCAutosomal Dominant Polycystic Kidney Disease (ADPKD)
Start: 2015-12-25End: 2016-12-21Updated: 2022-05-25
Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
CompletedNCT02616393
Kadmon Corporation, LLCBrain Metastases, Leptomeningeal Metastases, Non-Small Cell Lung Cancer
Start: 2015-11-30End: 2018-04-03Updated: 2022-03-16
Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
CompletedNCT02844439
Kadmon Corporation, LLCBrain Tumor, Glioblastoma, Recurrent Glioblastoma
Start: 2016-06-30End: 2020-04-30Updated: 2021-09-22
Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
CompletedNCT03203642
Kadmon, a Sanofi CompanyADPKD, Autosomal Dominant Polycystic Kidney
Start: 2017-10-12End: 2022-01-25Updated: 2023-02-06

Related Papers

Determination of the maximum tolerated dose (MTD) of the CNS penetrant tyrosine kinase inhibitor (TKI) tesevatinib administered in combination with trastuzumab in HER2+ patients with metastatic breast cancer (BC).
Journal of Clinical Oncology2016-05-2014 citations
A phase 1b trial of blood-brain barrier (BBB)-penetrant tyrosine kinase inhibitor (TKI) tesevatinib in combination with trastuzumab for patients with HER2+ metastatic breast cancer (MBC).
Journal of Clinical Oncology2015-05-203 citations